Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to mRNA-1273 booster after CoronaVac or ChAdOx1 COVID-19 vaccination
TCTR20211115003Recruiting
- Sponsor
- Thammasat University Hospital
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Thammasat University Hospital. Primary endpoint: Immune response to mRNA-1273 booster. Started Nov 2021; status: recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20211115003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211115003.